{
    "topic": "banking_and_finance",
    "source": "Independent Journal Review",
    "bias": 2,
    "url": "https://ijr.org/gilead-charging-5-day-coronavirus-treatments-price-2340/",
    "title": "Gilead Sets Price at $3,120 Per Patient With Private Insurance for Coronavirus Drug Remdesivir",
    "date": "2020-06-29",
    "authors": "Meaghan Ellis",
    "content": "Gilead Sciences unveiled the cost of its five-day coronavirus treatment .\nOn Monday , Gilead Chairman and CEO Daniel O \u2019 Day penned an open letter outlining the costs for remdesivir treatments .\nThe cost will be $ 2,340 per COVID-19 patient for Medicare and \u201c governments of developed countries , \u201d which equates to approximately $ 390 per vial . However , a U.S. patient with private health insurance will be charged $ 3,120 \u2014 an estimated minimum of $ 520 per vial \u2014 or up to $ 5,720 per patient for a longer duration .\nHowever , O \u2019 Day insists the prices actually below market value in an effort to offer \u201c broad and equitable access . \u201d\n\u201c As with many other aspects of this pandemic , we are in uncharted territory in pricing remdesivir , \u201d O \u2019 Day wrote . \u201c Ultimately , we were guided by the need to do things differently . \u201d\nHe continued , \u201c As the world continues to reel from the human , social and economic impact of this pandemic , we believe that pricing remdesivir well below value is the right and responsible thing to do . \u201d\nWe announced the price today for our investigational antiviral for the treatment of COVID-19 . We believe our unique approach will provide broad and equitable access . Read more from our Chairman & CEO : https : //t.co/rrEbrDxrLk . pic.twitter.com/9ElSExqSU3 \u2014 Gilead Sciences ( @ GileadSciences ) June 29 , 2020\nIn the letter , O \u2019 Day also confirmed that the company had entered into various agreements with drug manufacturers capable of producing generic forms of the drug in developing countries . The company expects to begin charging in July .\nGilead \u2019 s announcement about remdesivir comes amid doctors \u2019 and medical experts \u2019 scrutiny of the drug .\nWhile the cost outlined covers five days of treatment , a medical publication previously noted that remdesivir reduced recovery time by an average of four days based on a 10-day course of remdesivir .\nMultiple doctors and medical experts have also echoed similar sentiments expressing concern about the cost compared to the benefit and the results of healthcare as a big business .\nSome have also argued that clinical studies have not yet indicated whether or not there is even a mortality benefit that can justify the cost .\n\u201c Gilead Sciences charging $ 2,340 for a 5-day course of Remdesivir that maybe reduces time to recovery , doesn \u2019 t improve survival , \u201d Dr. Eugene Gu tweeted , adding , \u201c And is likely inferior to the much cheaper dexamethasone for ventilated patients reveals Big Pharma \u2019 s greed and opportunism during this pandemic . \u201d\nGilead Sciences charging $ 2,340 for a 5-day course of Remdesivir that maybe reduces time to recovery , doesn \u2019 t improve survival , and is likely inferior to the much cheaper dexamethasone for ventilated patients reveals Big Pharma \u2019 s greed and opportunism during this pandemic . \u2014 Eugene Gu , MD ( @ eugenegu ) June 29 , 2020\nRemdesivir price is out now . As I suspected , it \u2019 s not cheap\nGilead is charging hospitals between $ 3,120 and $ 5,720 per patient\nPayment will begin in July , likely in anticipation of making a profit in the second wave of COVID-19\nLot of money for a drug w/ no mortality benefit . https : //t.co/DsPvNc4NBx \u2014 James Todaro , MD ( @ JamesTodaroMD ) June 29 , 2020\nGilead receives $ 37.5M grant to develop/test Remdesivir\u2014courtesy of US taxpayers\nGilead projected 2020 revenue for Remdesivir : $ 1,000,000,000 \u2014 James Todaro , MD ( @ JamesTodaroMD ) May 4 , 2020\nDespite mounting concerns about the drug as a coronavirus treatment , Dr. Anthony Fauci touted the drug previously as he insisted it shows promise .",
    "content_original": "Gilead Sciences unveiled the cost of its five-day coronavirus treatment.\n\nOn Monday, Gilead Chairman and CEO Daniel O\u2019Day penned an open letter outlining the costs for remdesivir treatments.\n\nThe cost will be $2,340 per COVID-19 patient for Medicare and \u201cgovernments of developed countries,\u201d which equates to approximately $390 per vial. However, a U.S. patient with private health insurance will be charged $3,120 \u2014 an estimated minimum of $520 per vial \u2014 or up to $5,720 per patient for a longer duration.\n\nHowever, O\u2019Day insists the prices actually below market value in an effort to offer \u201cbroad and equitable access.\u201d\n\n\u201cAs with many other aspects of this pandemic, we are in uncharted territory in pricing remdesivir,\u201d O\u2019Day wrote. \u201cUltimately, we were guided by the need to do things differently.\u201d\n\nHe continued, \u201cAs the world continues to reel from the human, social and economic impact of this pandemic, we believe that pricing remdesivir well below value is the right and responsible thing to do.\u201d\n\nWe announced the price today for our investigational antiviral for the treatment of COVID-19. We believe our unique approach will provide broad and equitable access. Read more from our Chairman & CEO: https://t.co/rrEbrDxrLk. pic.twitter.com/9ElSExqSU3 \u2014 Gilead Sciences (@GileadSciences) June 29, 2020\n\nIn the letter, O\u2019Day also confirmed that the company had entered into various agreements with drug manufacturers capable of producing generic forms of the drug in developing countries. The company expects to begin charging in July.\n\nGilead\u2019s announcement about remdesivir comes amid doctors\u2019 and medical experts\u2019 scrutiny of the drug.\n\nWhile the cost outlined covers five days of treatment, a medical publication previously noted that remdesivir reduced recovery time by an average of four days based on a 10-day course of remdesivir.\n\nMultiple doctors and medical experts have also echoed similar sentiments expressing concern about the cost compared to the benefit and the results of healthcare as a big business.\n\nSome have also argued that clinical studies have not yet indicated whether or not there is even a mortality benefit that can justify the cost.\n\n\u201cGilead Sciences charging $2,340 for a 5-day course of Remdesivir that maybe reduces time to recovery, doesn\u2019t improve survival,\u201d Dr. Eugene Gu tweeted, adding, \u201cAnd is likely inferior to the much cheaper dexamethasone for ventilated patients reveals Big Pharma\u2019s greed and opportunism during this pandemic.\u201d\n\nGilead Sciences charging $2,340 for a 5-day course of Remdesivir that maybe reduces time to recovery, doesn\u2019t improve survival, and is likely inferior to the much cheaper dexamethasone for ventilated patients reveals Big Pharma\u2019s greed and opportunism during this pandemic. \u2014 Eugene Gu, MD (@eugenegu) June 29, 2020\n\nRemdesivir price is out now. As I suspected, it\u2019s not cheap\n\n\n\nGilead is charging hospitals between $3,120 and $5,720 per patient\n\n\n\nPayment will begin in July, likely in anticipation of making a profit in the second wave of COVID-19\n\n\n\nLot of money for a drug w/ no mortality benefit. https://t.co/DsPvNc4NBx \u2014 James Todaro, MD (@JamesTodaroMD) June 29, 2020\n\nGilead receives $37.5M grant to develop/test Remdesivir\u2014courtesy of US taxpayers\n\n\n\nTaxpayer funded study shows small non-mortality benefit\u2026FDA approves Remdesivir\n\n\n\nPatient cost: $1000\n\n\n\nRemdesivir manufacture cost: $10\n\n\n\nGilead projected 2020 revenue for Remdesivir: $1,000,000,000 \u2014 James Todaro, MD (@JamesTodaroMD) May 4, 2020\n\nDespite mounting concerns about the drug as a coronavirus treatment, Dr. Anthony Fauci touted the drug previously as he insisted it shows promise.\n\nPublished in",
    "source_url": "www.ijr.org",
    "bias_text": "right",
    "ID": "KUwIbCu0MbHUhgnR"
}